Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

Published:2018-03-29 Issue:3 Volume:25 Page:198-204
ISSN:0969-7128
Container-title:Gene Therapy
language:en
Short-container-title:Gene Ther

Author:

Zhang Wen-ying,Liu Yang,Wang Yao,Nie Jing,Guo Ye-lei,Wang Chun-meng,Dai Han-ren,Yang Qing-ming,Wu Zhi-qiang,Han Wei-dong

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/s41434-017-0001-8.pdf

Reference20 articles.

1. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.

2. Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep. 2016;11:368–84.

3. Oluwole OO, Davila ML. At the bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies. J Leukoc Biol. 2016;100:1265–72.

4. Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165–83.

5. Dai HR, Zhang WY, Li SX, Han QW, Guo YL, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4:e1027469.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing sortase A transpeptidation for advanced targeted therapeutics and vaccine engineering;Biotechnology Advances;2023-05

2. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma;Cancer Biology & Medicine;2023-03-02

3. Visualizing CAR-T cell Immunotherapy Using 3 Tesla Fluorine-19 MRI;Molecular Imaging and Biology;2021-11-16

4. The methods and advances of adaptive immune receptors repertoire sequencing;Theranostics;2021

5. Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system;Frontiers of Medicine;2020-08-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3